Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice
Armin Rehm, Anthea Wirges, Dana Hoser, Cornelius Fischer, Stefanie Herda, Kerstin Gerlach, Sascha Sauer, Gerald Willimsky, Uta E. Höpken
Armin Rehm, Anthea Wirges, Dana Hoser, Cornelius Fischer, Stefanie Herda, Kerstin Gerlach, Sascha Sauer, Gerald Willimsky, Uta E. Höpken
View: Text | PDF
Research Article Immunology Oncology

EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice

  • Text
  • PDF
Abstract

Insight into processes that determine CD8+ T cell memory formation has been obtained from infection models. These models are biased toward an inflammatory milieu and often use high-avidity CD8+ T cells in adoptive-transfer procedures. It is unclear whether these conditions mimic the differentiation processes of an endogenous repertoire that proceed upon noninflammatory conditions prevailing in premalignant tumor lesions. We examined the role of cytolytic capacity on CD8+ T cell fate decisions when primed by tumor cells or by minor histocompatibility antigen–mismatched leukocytes. CD8+ memory commitment was analyzed in Ebag9-deficient mice that exhibited enhanced tumor cell lysis. This property endowed Ebag9–/– mice with extended control of Tcl-1 oncogene–induced chronic lymphocytic leukemia progression. In Ebag9–/– mice, an expanded memory population was obtained for anti-HY and anti–SV-40 T antigen–specific T cells, despite unchanged effector frequencies in the primary response. By comparing the single-cell transcriptomes of CD8+ T cells responding to tumor cell vaccination, we found differential distribution of subpopulations between Ebag9+/+ and Ebag9–/– T cells. In Ebag9–/– cells, these larger clusters contained genes encoding transcription factors regulating memory cell differentiation and anti-apoptotic gene functions. Our findings link EBAG9-controlled cytolytic activity and the commitment to the CD8+ memory lineage.

Authors

Armin Rehm, Anthea Wirges, Dana Hoser, Cornelius Fischer, Stefanie Herda, Kerstin Gerlach, Sascha Sauer, Gerald Willimsky, Uta E. Höpken

×

Figure 2

Ebag9–/– mice develop a larger pool of HY-reactive memory CD8+ T cells.

Options: View larger image (or click on image) Download as PowerPoint
Ebag9–/– mice develop a larger pool of HY-reactive memory CD8+ T cells.
...
(A) Female WT (B6; +/+) and Ebag9–/– (–/–) mice were immunized (immuniz.) twice i.p. with 5 × 106 male splenocytes (HY+). (B) Splenic HY-specific CD8+ T cells were measured at day 10 or 11 by anti-CD8 and Db Uty Pentamer staining. (C) Representative FACS plots are shown; gated populations represent percentages of Pentamer/HY-positive cells within the CD8+ population. Bars indicate mean values ± SEM; n = 3 independent experiments with WT (n = 7), KO (n = 5), and naive (n = 3) animals. A Mann-Whitney test was applied. (D) Immunization scheme. At days 44–48 after the last immunization, CD8+ T cells were restimulated in vitro for 3 days with HY-peptide–pulsed DCs. (E) Mean frequency of the CD8+/HY+ Pentamer of CD8+ T cells; (right) absolute numbers of all splenocytes; unpaired Student’s t test of 3 independent experiments with WT (n = 11) and KO (n = 8) mice. (F) Immunization scheme. At days 133–147 after the first immunization, mice were challenged with female and male splenocytes (1:1) labeled with different amounts of eFluor-670. The ratio of both populations was determined by flow cytometry 22 hours later. (G) Histograms show representative examples per group. (H) Specific in vivo killing reported as percentages. Bars represent mean ± SEM of 2 experiments with naive (n = 3), WT (n = 3), and Ebag9–/– (n = 5) mice per group. A Mann-Whitney test was used for the analysis. (I) Mice were immunized as in D; HY-specific CD8+ T cells were detected with Db/HY Dextramers, without DC-HY peptide restimulation; n = 3 independent experiments. Representative dot plots of CD8+ Dextramer/HY+ CD44hi TCM and TEM cells. Numbers in the gates are the percentages of TCM and TEM cells. (J) Frequency as percentages of TEM and TCM among all CD8+CD44hi HY-specific T cells. Student’s t test was applied; each dot represents data from 1 mouse (WT, n = 11; KO, n = 8).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts